Q3 2025 Earnings Call Transcript May 14, 2025 Aytu BioPharma, Inc. beats earnings expectations. Reported EPS is $0.2, ...

Third Quarter 2025 Results Key Financial Results Revenue: US$18.5m (up 2.6% from ...

Boot Barn shares jumped 14.7% to $152.31 in the pre-market trading session. Here are some other stocks moving in pre-market ...

Aytu BioPharma Inc (AYTU) reports significant revenue growth and operational income, despite challenges in gross margins and acquisition valuations.

Discover how Aytu BioPharma achieved 32% revenue growth in Q3 2025, with record numbers in ADHD and pediatric portfolios, signaling strong momentum ahead.

Net income of $4.0 million, or $0.65 and $0.21 net income per share basic and diluted, respectivelyAdjusted EBITDA1 of $3.9 millionTotal net revenue of $18.5 million up 32% year-over-yearCompany to ...

Aytu BioPharma (NASDAQ:AYTU) is scheduled to announce Q3 earnings results on Wednesday, May 14th, after market close. The consensus EPS Estimate is -$0.17 and the consensus Revenue Estimate is $13.74M ...

DENVER, CO / ACCESS Newswire / May 7, 2025 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, will report its ...

Now it’s at $568, and that’s after 6.87% beating today. Regeneron is arguably the most innovative biopharma company I’ve seen in the last two decades. But the stock’s come in significantly ...

CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing ...

A biopharmaceutical company in Hinjewadi fell victim to a ransomware attack, with cybercriminals demanding $80,000 for the release of encrypted data. The Pimpri Chinchwad police are investigating ...

Biopharma venture funding dropped 20% in the first quarter of 2025 compared to the same period the year before, according to GlobalData. Worldwide venture financing for the sector experienced a ...